Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Dinorencel Injection (or RC19D2 Cell Injection) in the Treatment of CD19-positive Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT06047197 is registered in ClinicalTrials.gov with Beijing Yongtai Ruike Biotechnology Company Ltd as lead sponsor.

NCT NCT06047197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06047197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Dinorencel Injection (or RC19D2 Cell Injection) in the Treatment of CD19-positive Relapsed or Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Beijing Yongtai Ruike Biotechnology Company Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 5, 2023
Completion date
December 5, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma